INTENSITY THERAPEUTICS, INC. (INTS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
8/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseINTS / S&P -30.27% / 15.20% |
LoseINTS / S&P INTS unavailable / 15.00% |
LoseINTS / S&P -72.31% / 50.40% |
| 2026-Q10/3 |
LoseINTS / S&P -42.63% / -4.33% |
LoseINTS / S&P INTS unavailable / 11.30% |
LoseINTS / S&P -63.35% / 27.70% |
| 2025-Q41/3 |
WinINTS / S&P 68.72% / 2.65% |
LoseINTS / S&P INTS unavailable / 9.00% |
LoseINTS / S&P -41.31% / 13.40% |
| 2025-Q31/3 |
LoseINTS / S&P -20.85% / 8.12% |
LoseINTS / S&P INTS unavailable / 4.61% |
WinINTS / S&P 3378.50% / 13.45% |
| 2025-Q21/3 |
LoseINTS / S&P -84.42% / 10.94% |
LoseINTS / S&P INTS unavailable / 4.83% |
WinINTS / S&P 3678.79% / 10.63% |
| 2025-Q12/3 |
WinINTS / S&P 11.93% / -4.27% |
LoseINTS / S&P INTS unavailable / 4.98% |
WinINTS / S&P 1570.39% / 10.57% |
| 2024-Q41/3 |
LoseINTS / S&P -53.93% / 2.41% |
LoseINTS / S&P INTS unavailable / 5.25% |
WinINTS / S&P 1285.78% / 6.15% |
| 2024-Q30/3 |
LoseINTS / S&P -22.04% / 5.89% |
LoseINTS / S&P INTS unavailable / 5.89% |
LoseINTS / S&P -55.97% / 6.11% |
| 2024-Q20/3 |
LoseINTS / S&P -5.77% / 4.28% |
LoseINTS / S&P INTS unavailable / 5.38% |
LoseINTS / S&P -64.39% / 5.12% |
| 2024-Q11/3 |
LoseINTS / S&P -39.32% / 10.56% |
LoseINTS / S&P INTS unavailable / 5.71% |
WinINTS / S&P 7.29% / 5.59% |
| 2023-Q41/3 |
WinINTS / S&P 115.87% / 11.69% |
LoseINTS / S&P INTS unavailable / 6.81% |
LoseINTS / S&P INTS unavailable / 7.78% |
| 2023-Q30/3 |
LoseINTS / S&P -33.39% / -3.27% |
LoseINTS / S&P INTS unavailable / 7.52% |
LoseINTS / S&P INTS unavailable / -5.03% |
| 2023-Q20/3 |
LoseINTS / S&P INTS unavailable / 8.74% |
LoseINTS / S&P INTS unavailable / 9.50% |
LoseINTS / S&P INTS unavailable / -8.57% |
| 2023-Q10/3 |
LoseINTS / S&P INTS unavailable / 7.50% |
LoseINTS / S&P INTS unavailable / 10.77% |
LoseINTS / S&P INTS unavailable / -15.69% |
| 2022-Q40/3 |
LoseINTS / S&P INTS unavailable / 7.56% |
LoseINTS / S&P INTS unavailable / 11.88% |
LoseINTS / S&P INTS unavailable / -17.99% |
| 2022-Q30/3 |
LoseINTS / S&P INTS unavailable / -4.88% |
LoseINTS / S&P INTS unavailable / 13.47% |
LoseINTS / S&P INTS unavailable / -1.41% |
| 2022-Q20/3 |
LoseINTS / S&P INTS unavailable / -16.10% |
LoseINTS / S&P INTS unavailable / 13.71% |
LoseINTS / S&P INTS unavailable / 11.04% |
| 2022-Q10/3 |
LoseINTS / S&P INTS unavailable / -4.60% |
LoseINTS / S&P INTS unavailable / 15.97% |
LoseINTS / S&P INTS unavailable / 42.23% |
| 2021-Q40/3 |
LoseINTS / S&P INTS unavailable / 11.03% |
LoseINTS / S&P INTS unavailable / 15.00% |
LoseINTS / S&P INTS unavailable / 96.40% |
| 2021-Q30/3 |
LoseINTS / S&P INTS unavailable / 0.58% |
LoseINTS / S&P INTS unavailable / 10.77% |
LoseINTS / S&P INTS unavailable / 69.42% |
| 2021-Q20/3 |
LoseINTS / S&P INTS unavailable / 8.55% |
LoseINTS / S&P INTS unavailable / 6.58% |
LoseINTS / S&P INTS unavailable / 51.81% |
| 2021-Q10/3 |
LoseINTS / S&P INTS unavailable / 6.17% |
LoseINTS / S&P INTS unavailable / -1.06% |
LoseINTS / S&P INTS unavailable / 7.39% |
| 2020-Q40/3 |
LoseINTS / S&P INTS unavailable / 12.15% |
LoseINTS / S&P INTS unavailable / -3.72% |
LoseINTS / S&P INTS unavailable / -33.42% |
| 2020-Q30/3 |
LoseINTS / S&P INTS unavailable / 8.93% |
LoseINTS / S&P INTS unavailable / -2.04% |
LoseINTS / S&P INTS unavailable / -27.10% |
| 2020-Q20/3 |
LoseINTS / S&P INTS unavailable / 20.54% |
LoseINTS / S&P INTS unavailable / -0.46% |
LoseINTS / S&P INTS unavailable / -27.11% |
| 2020-Q10/3 |
LoseINTS / S&P INTS unavailable / -19.60% |
LoseINTS / S&P INTS unavailable / 3.47% |
LoseINTS / S&P INTS unavailable / -14.75% |
| 2019-Q40/3 |
LoseINTS / S&P INTS unavailable / 9.07% |
LoseINTS / S&P INTS unavailable / 5.36% |
LoseINTS / S&P INTS unavailable / 2.99% |
| 2019-Q30/3 |
LoseINTS / S&P INTS unavailable / 1.70% |
LoseINTS / S&P INTS unavailable / 5.02% |
LoseINTS / S&P INTS unavailable / 0.21% |
| 2019-Q20/3 |
LoseINTS / S&P INTS unavailable / 4.30% |
LoseINTS / S&P INTS unavailable / 6.64% |
LoseINTS / S&P INTS unavailable / 8.65% |
| 2019-Q10/3 |
LoseINTS / S&P INTS unavailable / 13.65% |
LoseINTS / S&P INTS unavailable / 8.12% |
LoseINTS / S&P INTS unavailable / 14.29% |
| 2018-Q40/3 |
LoseINTS / S&P INTS unavailable / -13.52% |
LoseINTS / S&P INTS unavailable / 9.05% |
LoseINTS / S&P INTS unavailable / 18.23% |
| 2018-Q30/3 |
LoseINTS / S&P INTS unavailable / 7.71% |
LoseINTS / S&P INTS unavailable / 10.21% |
LoseINTS / S&P INTS unavailable / 19.06% |
| 2018-Q20/3 |
LoseINTS / S&P INTS unavailable / 3.43% |
LoseINTS / S&P INTS unavailable / 9.03% |
LoseINTS / S&P INTS unavailable / 14.46% |
| 2018-Q10/3 |
LoseINTS / S&P INTS unavailable / -0.76% |
LoseINTS / S&P INTS unavailable / 7.68% |
LoseINTS / S&P INTS unavailable / 12.46% |
| 2017-Q40/3 |
LoseINTS / S&P INTS unavailable / 6.64% |
LoseINTS / S&P INTS unavailable / 7.03% |
LoseINTS / S&P INTS unavailable / 13.82% |
| 2017-Q30/3 |
LoseINTS / S&P INTS unavailable / 4.48% |
LoseINTS / S&P INTS unavailable / 5.68% |
LoseINTS / S&P INTS unavailable / 17.57% |
| 2017-Q20/3 |
LoseINTS / S&P INTS unavailable / 3.09% |
LoseINTS / S&P INTS unavailable / 4.83% |
LoseINTS / S&P INTS unavailable / 17.74% |
| 2017-Q10/3 |
LoseINTS / S&P INTS unavailable / 6.07% |
LoseINTS / S&P INTS unavailable / 3.67% |
LoseINTS / S&P INTS unavailable / 13.32% |
| 2016-Q40/3 |
LoseINTS / S&P INTS unavailable / 3.82% |
LoseINTS / S&P INTS unavailable / 2.09% |
LoseINTS / S&P INTS unavailable / 7.05% |
| 2016-Q30/3 |
LoseINTS / S&P INTS unavailable / 3.85% |
LoseINTS / S&P INTS unavailable / 0.20% |
LoseINTS / S&P INTS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -39.43% | 20.78% |
| Annualized return | -39.43% | 20.78% |
5Y · 2023-06-30 to 2026-08-27
| Metric | INTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.13% | 83.14% |
| Annualized return | -50.86% | 12.86% |
10Y · 2023-06-30 to 2026-08-27
| Metric | INTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.13% | 319.30% |
| Annualized return | -29.90% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |